Home About Cytheris Corporate Overview Executive Management Board of Directors Clinical Advisory Board Academic Partners History Science Portfolio Overview Interleukin-7 NKT Ligands Pipeline & Products Development Pipeline IL-7 in Oncology IL-7 in HIV IL-7 in HCV NKT Ligands Intellectual Property Manufacturing Clinical Trials Clinical Trials Overview IL-7 Oncology Trials IL-7 HIV Trials IL-7 HCV Trials Other IL-7 Trials Business Development News Room Press Releases Calendar of Events Investors Careers Contact Us

Press Releases 2004
January 12, 2004
	Cytheris Initiates Phase I Clinical Trial of its First Recombinant Protein, CYT 99 007, and Expands Its Board
	FR